Universität zu Köln

2018

Merseburger, A., Carl, S., Feyerabend, S., Gleissner, J., Grimm, M. -O., Gruellich, C., Heidenreich, A., Heinrich, B., Miller, K., Stenzl, A., Steuber, T., Wirth, M., Watkins, S., Simmons, A., Passler, L., Shetty, S., Golsorkhi, T., Ryan, C. and Chowdhury, S. (2018). TRITON3: An International, Randomised, Open-Label Phase 3 Study of the PARP Inhibitor Rucaparib vs Physician's Choice of Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Associate with Homologous Recombination Deficiency (HRD). Oncol. Res. Treat., 41. S. 74 - 75. BASEL: KARGER. ISSN 2296-5262

2017

Chowdhury, S., Abida, W., Arranz Arija, J., Daugaard, G., Fizazi, K., Gez, E., Heidenreich, A., Joly Lobbedez, F., McDermott, R., Merseburger, A. S., Piulats Rodriguez, J. M., Sautois, B., Sridhar, S., Sternberg, C. N., Watkins, S., Simmons, A., Shetty, S., Golsorkhi, A., Ryan, C. J. and Scher, H. (2017). The TRITON clinical trial programme: Evaluation of the PARP inhibitor rucaparib in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD). Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Corcoran, N. M., Heidenreich, A., Shore, N., Villers, A., Klotz, L., Siemens, D. R., van Os, S., Baron, B., Wang, F. and Chowdhury, S. (2017). Prognostic Factors in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide (ENZA) Or Bicalutamide (BIC) in Terrain. Asia-Pac. J. Clin. Oncol., 13. S. 57 - 58. HOBOKEN: WILEY. ISSN 1743-7563

2016

Chowdhury, S., Shore, N., Saad, F., Higano, C. S., Fizazi, K., Iversen, P., Miller, K., Heidenreich, A., Ueda, T., Kim, C. S., Phung, D., Krivoshik, A., Wang, F., Wu, K. and Tombal, B. (2016). Fatigue in men with metastatic castration-resistant prostate cancer treated with enzalutamide: data from randomised clinical trials. Ann. Oncol., 27. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Heidenreich, A., Shore, N., Villers, A., Klotz, L., Siemens, D. R., van Os, S., Baron, B., Wang, F. and Chowdhury, S. (2016). Prognostic factors in men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA) or bicalutamide (BIC) in TERRAIN. Ann. Oncol., 27. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041